Pei-Jia Yang

Title: Pei-Jia Yang: Innovator in Cancer Immunotherapy

Introduction

Pei-Jia Yang is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer immunotherapy through his innovative research and patent developments. His work focuses on identifying and ranking immunogenic T-cell epitopes, which are crucial for developing personalized cancer treatments.

Latest Patents

Pei-Jia Yang holds a patent titled "Ranking system for immunogenic cancer-specific epitopes." This patent relates to systems and methods that identify, predict, and rank immunogenic T-cell epitopes. Specifically, it identifies epitopes arising from disease-associated mutations, which are predicted to elicit immune responses from T cells. The system considers both peptide-level information, including MHC Class I and II presentation, and sample-level information, such as mutation clonality and MHC allele dosage. This innovative approach has the potential to enhance personalized treatment strategies for cancer patients.

Career Highlights

Throughout his career, Pei-Jia Yang has demonstrated a commitment to advancing cancer research. His work has been instrumental in developing methods that improve the understanding of immune responses to cancer. He has been recognized for his contributions to the scientific community and continues to be an influential figure in his field.

Collaborations

Pei-Jia Yang has collaborated with notable colleagues, including Jen-Hao Cheng and Ying-Ja Chen. These collaborations have further enriched his research and contributed to the advancement of cancer immunotherapy.

Conclusion

Pei-Jia Yang's innovative work in identifying immunogenic T-cell epitopes represents a significant advancement in cancer treatment. His contributions are paving the way for more effective personalized therapies, ultimately benefiting patients worldwide.